Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual

Jun 08, 2021 7:00 PM - Jun 11, 2021 12:00 AM

(Central Europe Standard Time)

Future of Evidence and Smart Health Conference

Leveraging RWE to advance healthcare decision-making.

Session 4: Application of AI & ML in Drug Development and Approval

Session Chair(s)

Niels Buch Leander, PhD

Niels Buch Leander, PhD

Vice President, R&D

NNIT, Denmark

This session will bring together leading technology providers to combine a focus on the drug development approval process with the data stemming from patients’ use of the medicine approved. From Regulatory Affairs, the perspective is on streamlining the approval process by reference to the right data and on demonstrating and maintaining a safety profile, supported by the patients’ observations. However, the role of the patient is rapidly changing due to technology, and this session will demonstrate and discuss the technologies that will potentially transform the approval process and the safety monitoring of the drugs.

Speaker(s)

Niels Buch Leander, PhD

Intro - Application of AI & ML in Drug Development and Approval

Niels Buch Leander, PhD

NNIT, Denmark

Vice President, R&D

Susant  Mallick, MBA

Embracing Real World Evidence (RWE) & Robotic Process Automation to transform Regulatory Affairs Submission Process

Susant Mallick, MBA

Cloudhub BV, Netherlands

Founder and CEO, Life Sciences Practice Leader

Niels  Gronning, MSc

AI and ML in a Drug Development Perspective

Niels Gronning, MSc

Microsoft, Denmark

Senior Specialist

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.